References
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-20. 10.1007/s00401-016-1545-1
- Czarnek N, Clark K, Peters KB, Mazurowski MA. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. J Neurooncol 2017; 132: 55-62. 10.1007/s11060-016-2359-7
- Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci 2014; 15: 455-65. 10.1038/ nrn3765
- Roos A, Ding Z, Loftus JC, Tran NL. Molecular and microenvironmental determinants of glioma stem-like cell survival and invasion. Front Oncol 2017; 7: 120. 10.3389/fonc.2017.00120
- Mentlein R, Hattermann K, Held-Feindt J. Lost in disruption: role of proteases in glioma invasion and progression. Biochim Biophys Acta 2012; 1825: 178-85. 10.1016/j.bbcan.2011.12.001
- Colin, C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagliata D, et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 2009; 118: 745-54. 10.1007/s00401-009-0592-2
- Gole B, Huszthy PC, Popović M, Jeruc J, Ardebili YS, Bjerkvig R, et al. The regulation of cysteine cathepsins and cystatins in human gliomas. Int J Cancer 2012; 131: 1779-89. 10.1002/ijc.27453
- Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer 2015; 15: 712-29. 10.1038/nrc4027
- Kenig S, Frangež R, Pucer A, Lah T. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis 2011; 16: 671-82. 10.1007/s10495-011-0600-6
- Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, et al. Cathepsin L, target in cancer treatment? Life Sci 2010; 86: 225-33. 10.1016/j.lfs.2009.11.016
- Breznik B, Motaln H, Turnšek TL. Proteases and cytokines as mediators of interactions between cancer and stromal cells in tumours. Biol Chem 2017; 398: 709-19. 10.1515/hsz-2016-0283
- Kramer L, Turk D, Turk B. The future of cysteine cathepsins in disease management. Trends Pharmacol Sci 2017; 38: 873-98. 10.1016/j. tips.2017.06.003
- López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-8. 10.1038/nrc2228
- Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31: 326-41. 10.1016/j.ccell.2017.02.009
- Lah TT, Duran Alonso MB, Van Noorden CF. Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 2006; 6: 257-79. 10.1517/14712598.6.3.257
- Lah TT, Obermajer N, Duran Alonso MB, Kos J. Cysteine cathepsins and cystatins as cancer biomarkers. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF, editors. The cancer degradome: proteases and cancer biology New York: Springer; 2008. p. 575-613.
- Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int J Cancer 2006; 119: 854-60. 10.1002/ijc.21911
- Verbovšek U, Motaln H, Rotter A, Atai NA, Gruden K, Van Noorden CJ, et al. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma PLoS One 2014; 9: e111819. 10.1371/ journal.pone.0111819
- Verbovšek U, Van Noorden CJ, Lah TT. Complexity of cancer protease biology: cathepsin K expression and function in cancer progression. Semin Cancer Biol 2015; 35: 71-84. 10.1016/j.semcancer.2015.08.010
- Novinec M, Lenarčič B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 2013; 394: 1163-79. 10.1515/hsz-2013-0134
- Staudt ND, Maurer A, Spring B, Kalbacher H, Aicher WK, Klein G. Processing of CXCL12 by different osteoblast-secreted cathepsins. Stem Cells Dev 2012; 21: 1924-35. 10.1089/scd.2011.0307
- Hira VV, Verbovšek U, Breznik B, Srdič M, Novinec M, Kakar H, et al. Cathepsin K cleavage of SDF-1α inhibits its chemotactic activity towards glioblastoma stem-like cells. Biochim Biophys Acta 2017; 1864: 594-603. 10.1016/j.bbamcr.2016.12.021
- Kos J, Vižin T, Fonović UP, Pišlar A. Intracellular signaling by cathepsin X: molecular mechanisms and diagnostic and therapeutic opportunities in cancer. Semin Cancer Biol 2015; 31: 76-83. 10.1016/j.semcancer.2014.05.001
- Kos J, Jevnikar Z, Obermajer N. The role of cathepsin X in cell signaling. Cell Adh Migr 2009; 3: 164-6.
- Wendt W, Zhu XR, Lübbert H, Stichel CC. Differential expression of cathepsin X in aging and pathological central nervous system of mice. Exp Neurol 2007; 204: 525-40. 10.1016/j.expneurol.2007.01.007
- Nägler DK, Krüger S, Kellner A, Ziomek E, Menard R, Buhtz P, et al. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 2004; 60: 109-19. 10.1002/pros.20046
- Krueger S, Kalinski T, Hundertmark T, Wex T, Küster D, Peitz U, et al. Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer. J Pathol 2005; 207: 32-42. 10.1002/path.1820
- Vizin T, Christensen IJ, Nielsen HJ, Kos J. Cathepsin X in serum from patients with colorectal cancer: relation to prognosis. Radiol Oncol 2012; 46: 207-12. 10.2478/v10019-012-0040-0
- Gopinath S, Malla R, Alapati K, Gorantla B, Gujrati M, Dinh DH, et al. Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression. Carcinogenesis 2013; 34: 550-9. 10.1093/carcin/bgs375
- Alapati K, Kesanakurti D, Rao JS, Dasari VR. uPAR and cathepsin B-mediated compartmentalization of JNK regulates the migration of glioma-initiating cells. Stem Cell Res 2014; 12: 716-29. 10.1016/j.scr.2014.02.008
- Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev 2015; 29: 1203-17. 10.1101/ gad.261982.115
- Godlewski J, Ferrer-Luna R, Rooj AK, Mineo M, Ricklefs F, Takeda YS, et al. MicroRNA Signatures and molecular subtypes of glioblastoma: the role of extracellular transfer. Stem Cell Reports 2017; 8: 1497-505. 10.1016/j. stemcr.2017.04.024
- Hira VV, Ploegmakers KJ, Grevers F, Verbovšek U, Silvestre-Roig C, Aronica E, et al. CD133+ and nestin+ glioma stem-like cells reside around CD31+ arterioles in niches that express SDF-1α, CXCR4, osteopontin and cathepsin K. J Histochem Cytochem 2015; 63: 481-93. 10.1369/0022155415581689
- Hira VVV, Aderetti DA, van Noorden CJF. Glioma stem cell niches in human glioblastoma are periarteriolar. J Histochem Cytochem 2018; 66: 349-58. 10.1369/0022155417752676
- Hira VVV, Wormer JR, Kakar H, Breznik B, van der Swaan B, Hulsbos R, et al. Periarteriolar glioblastoma stem cell niches express bone marrow hematopoietic stem cell niche proteins. J Histochem Cytochem 2018; 66: 155-73. 10.1369/0022155417749174
- GlioVis: Data visualization tools for brain tumor datasets. 2017. [citated 20 Sep 2017]. Available from: http://gliovis.bioinfo.cnio.es/
- Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol 2017; 19: 139-41. 10.1093/neuonc/now247
- Završnik J, Butinar M, Trstenjak Prebanda M, Krajnc A, Vidmar R, Fonović M, et al. Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells. Oncotarget 2017; 8: 73793-809. 10.18632/oncotarget.17379
- Chieco P, Jonker A, De Boer BA, Ruijter JM, Van Noorden CJ. Image cytometry: protocols for 2D and 3D quantification in microscopic images. Prog Histochem Cytochem 2013; 47: 211-333. 10.1016/j.proghi.2012.09.001
- Segerman A, Niklasson M, Haglund C, Bergström T, Jarvius M, Xie Y, et al. Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition. Cell Rep 2016; 17: 29943009. 10.1016/j.celrep.2016.11.056
- Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110. 10.1016/j.ccr.2009.12.020
- Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-9. 10.1158/1078-0432.CCR-07-0932
- Kenig S, Alonso MB, Mueller MM, Lah TT. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett 2010; 289: 53-61. 10.1016/j.canlet.2009.07.014
- Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015; 16: 225-38. 10.1016/j.stem.2015.02.015
- Saito K, Hirai T, Takeshima H, Kadota Y, Yamashita S, Ivanova A, Yokogami K. Genetic factors affecting intraoperative 5-aminolevulinic acid-induced fluorescence of diffuse gliomas. Radiol Oncol 2017; 51:142-50. 10.1515/ raon-2017-0019
- Strojnik T, Kos J, Zidanik B, Golouh R, Lah T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999; 5: 559-67.
- Strojnik T, Kavalar R, Trinkaus M, Lah TT. Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 2005; 29: 448-55. 10.1016/j.cdp.2005.07.006
- Dauth S, Schmidt MM, Rehders M, Dietz F, Kelm S, Dringen R, et al. Characterisation and metabolism of astroglia-rich primary cultures from cathepsin K-deficient mice. Biol Chem 2012; 393: 959-70. 10.1515/ hsz-2012-0145
- Dauth S, Sîrbulescu RF, Jordans S, Rehders M, Avena L, Oswald J, et al. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci 2011; 12: 74. 10.1186/1471-2202-12-74
- Wang J, Chen L, Li Y, Guan XY. Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. PLoS One 2011; 6: e24967. 10.1371/journal. pone.0024967
- Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S, et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci US A 2010; 107: 2497-502. 10.1073/pnas.0907240107
- Mitrović A, Pečar Fonović U, Kos J. Cysteine cathepsins B and X promote epithelial-mesenchymal transition of tumor cells. Eur J Cell Biol 2017; 96: 622-31. 10.1016/j.ejcb.2017.04.003
- Akkari L, Gocheva V, Kester JC, Hunter KE, Quick ML, Sevenich L, et al. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev 2014; 28: 2134-50. 10.1101/gad.249599.114
- Euskirchen P, Radke J, Schmidt MS, Schulze Heuling E, Kadikowski E, Maricos M, et al. Cellular heterogeneity contributes to subtype-specific expression of ZEB1 in human glioblastoma. PLoS One 2017; 12: e0185376. 10.1371/journal.pone.0185376
- Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82. 10.1016/j.ccr.2006.11.020
- Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res 2011; 71: 6061-72. 10.1158/0008-5472.CAN-10-4269
- Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E, et al. CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol 2017; 19: 66-77. 10.1093/neuonc/now136
- Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S, et al. CD133/prominin1 is prognostic for GBM patient’s survival, but inversely correlated with cysteine cathepsins’ expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-15. 10.2478/v10019-011-0015-6
- Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006 ;12: 657–64. 10.1038/ nm1417
- MEROPS database: The peptidase database. [15 Dec 2017]. Citated https://www.ebi.ac.uk/merops/index.shtml.